Phase 3CompletedAge-related condition

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Japanese Women Going Through Menopause (Starlight 2)

A Phase 3, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Fezolinetant in Japanese Women Experiencing Vasomotor Symptoms (Hot Flashes) Associated With Menopause

Sponsor
Astellas Pharma Inc (Industry)
Enrollment
410 enrolled
Conditions
Hot Flashes
Interventions
Fezolinetant; Placebo
Ages
adults, older adults
Registry
NCT06206408, jRCT2031230571

Full record on ClinicalTrials.gov

From the registry

Hot flashes are the most common reason women going through menopause seek medical attention. Hormone replacement therapy, or HRT, is most often prescribed to treat hot flashes. However, HRT can't be used by all women or for as long as may be needed. Researchers want to find other ways to treat hot flashes. Fezolinetant is a medicine to treat hot flashes in women going through menopause. Fezolinetant is an approved medicine in the US. Further studies are needed before it is available in other regions such as Asia. This study will confirm if fezolintant helps reduce the number of hot flashes in Japanese women going through menopause. Women that want to take part in the study will be given an electronic handheld device with an app to track their hot flashes. Some women may be able to use the app on their own smartphone. Before the women are assigned a treatment, they will record information about their hot flashes. Women will either take a lower or higher dose of fezolinetant, or a placebo. This is decided by chance alone. The placebo looks like fezolinetant but will not have any…

Primary outcomes

  • Mean change from baseline in the frequency of mild to severe vasomotor symptoms (VMS)

History

  1. Last registry update

  2. Study completion

  3. Primary completion

  4. Started

  5. Registered